Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer With 31.43% Upside Potential

Septerna, Inc. (SEPN) Stock Analysis: Biotechnology Pioneer With 31.43% Upside Potential

Septerna, Inc. (SEPN), a burgeoning name in the biotechnology sector, has captured investor attention with its remarkable revenue growth and potential upside. As a clinical-stage biotech company, Septerna is pioneering innovative treatments in endocrinology, immunology, and metabolic diseases by developing G protein-coupled receptor (GPCR) oral small molecule products. Headquartered in South San Francisco, California, and with a market cap of $1…